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Sa semiquantitative scale after the following stainings: hematoxylin eosin (for
assessment of intra- and extracellular lipids and for assessment of thrombus
formation), Elastica van Gieson, anti-CD31 for assessment of vessel density, anti-
CD68, anti-CD3 and anti-CD15 for analysis of local inﬂammation, anti-SMC actin
to stain smooth muscle cells, anti-CD61 for platelet depositions, TUNEL staining
for apoptotic cells.
Results: Lipid and foam cell content was most pronounced in aortic lesions (P¼0.02,
P¼0.04), calciﬁcation and SMC actin in femoral lesions (P¼0.001, P¼0.001), CD3+
cells in carotid lesions (P¼0.004) and TUNEL+ apoptotic cells in coronary lesions
(P¼0.01). Thrombus was most prevalent in carotid and aortic lesions (P¼0.02).
Neutrophil (CD15+) and monocyte (CD68+) cell inﬁltrations as well as vessel density
were most pronounced in carotid and femoral lesions (P¼0.04, P¼0.02, P¼0.005). No
signiﬁcant changes were observed in vessel hemorrhage or platelet content. These
results suggest more inﬂammatory lesions in carotid and femoral arteries with an
increase in calciﬁcation and SMC content in femoral lesions as compared to more lipid
rich lesions within the aorta and an increase in apoptotic cells within coronary lesions.
Additionally, gene expression of atherosclerosis related genes in carotid and femoral
endaterectomy specimen was measured. An overall increased metabolism was found
in femoral plaques, especially genes concerning inﬂammatory response, response to
stress, apoptosis, adhesion, whereas in carotid lesions, we detected overexpression of
genes related to lipid/cholesterol transport and metabolism and negative transcription
regulators.
Conclusions: Different arterial territories are differently affected by atherosclerosis:
Our results suggest more inﬂammatory lesions in carotid and femoral arteries with an
increase in calciﬁcation and SMC content in femoral lesions as compared to more lipid
rich lesions within the aorta and an increase in apoptotic cells within coronary lesions.
Concerning PAD, gene expression in atherosclerotic lesions shows signiﬁcant
differences. Understanding of the local differences of atherosclerosis may aid to
improve prevention and lead to targeted treatment of atherosclerosis and its
complicationsTCT-819
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Background: The Combo Dual Therapy stent (OrbusNeich Medical, Ft. Lauderdale,
FL) combines anti-proliferative abluminal sirolimus elution from a bioresorbable
matrix with luminal CD34 antibody endothelial progenitor cell capture. This study
compares the healing of the Combo stent to an everolimus-eluting stent [EES] (Xience
Prime; Abbott Vascular, Santa Clara, CA), along with the Genous stent (OrbusNeich)
as control.
Methods: 31 atherosclerotic rabbits were implanted with bilateral iliac stents and
survived for 28 days or 45 days. Select animals underwent assessment by OCT after
stent implant and again prior to sacriﬁce. To assess cellular proliferation, animals were
given BrdU before sacriﬁce. The stented arterial segments were designated for either
light microscopy evaluation or en face assessment by both SEM for endothelial
coverage and immuno confocal microscopy for expression of endothelial markers
CD31/PECAM and eNOS.
Results: At 28 days, morphometric comparison of areas measurements showed
statistically comparable EEL, IEL, lumen, stent, media, and plaque areas and
thicknesses between groups. Uncovered struts were seen in all groups with the
highest and statistically signiﬁcant frequency in EES > Combo > Genous. At
45 days, morphometric values remained relatively similar to day 28 with a slight
increase of stenosis seen with Genous. Endothelial coverage at 28 days above
struts by SEM was highest in Genous (98.3%), followed by Combo (83.3%),
and lowest in EES (52.7%) (p¼0.025). Endothelial coverage between struts was
nearly identical (Combo 93.3%, Genous 87.5%, EES 92.0%, p¼0.714). By
OCT, 28-day animals showed less area stenosis and less neointimal thickness in
Combo and EES as compared to Genous. There were no signiﬁcant differences
between Combo and EES in terms of area stenosis, neointimal thickness, and
uncovered struts. No stents showed thrombosis or restenosis at both 28-day and
45-day time points. The OCT analysis correlated signiﬁcantly with histologic
ﬁndings.
Conclusions: Compared to the EES stent, the Combo stent was found to have
a similar reduction in neointimal proliferation, while exhibiting fewer uncovered struts
and signiﬁcantly greater endothelial coverage over struts.B248 JACC Vol 62/18/Suppl B j October 27–November 1, 2013 jTCT-820
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Background: Increased expression of interferon (IFN)-beta was shown in patients
with insufﬁcient coronary collaterals. Furthermore, mice treated with IFN-beta
demonstrate inhibition of collateral artery growth (arteriogenesis). Interestingly,
type I interferons (IFN-alpha and IFN-beta) have been identiﬁed as proathero-
sclerotic cytokines and in mouse models of atherosclerosis, IFN-beta treatment
accelerated lesion formation and increased accumulation of macrophages in
plaques. We hypothesized that arteriogenesis can be stimulated using monoclonal
antibodies inhibiting IFN-beta signaling without accelerating atherosclerosis.
Methods: In an atherosclerotic murine hindlimb-ischemia model, LDLR-/- mice were
treated during a 4-week period with monoclonal antibodies speciﬁc for mouse
Interferon-alpha/beta Receptor subunit 1 (IFNAR-1) or murine IgG isotype as control.
Hindlimb perfusion was measured using laser Doppler perfusion imaging (LDPI)
directly after femoral artery ligation as well as at 2, 7, 14 and 28 days following
ligation. We used a disease model to investigate effects of anti-IFNAR-1 on athero-
sclerosis, which was evaluated with histology to determine plaque area and
composition.
Results: Hindlimb perfusion restoration after femoral artery ligation was improved
in mice treated with anti-IFNAR-1 compared to controls as assessed by LDPI after
7, 14 and 28 days (treatment vs. control; 7 days: 35.6  16.5% vs. 23.6  8.7%,
p¼0.027; 14 days: 51.4  17.2% vs. 35.0  12.3%, p 0.010; 28 days 71.5  13.8%
vs. 54.0  16.3%, p¼0.005). Total plaque area (treatment vs. control: 118.8 
46.1x103 mm2 vs. 139.3  46.5 x103 mm2, p¼0.275) as well as composition were
unaffected.
Conclusions: Blocking IFNAR-1 using monoclonal antibodies stimulates collateral
artery growth in mice and has a neutral effect on atherosclerosis.TCT-821
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Background: The REVIVAL-2 study showed that stem cell mobilization by G-CSF
does not inﬂuence infarct size, left ventricular function and coronary restenosis in
patients with AMI that underwent successful percutaneous coronary intervention
(PCI). The objective of the present analysis was to assess the impact of G-CSF
treatment on 5-year clinical outcomes from the REVIVAL-2 trial.
Methods: In the randomized, double-blind, placebo-controlled REVIVAL-2 study,
114 patients with the diagnosis of acute myocardial infarction were enrolled 5 days
after successful reperfusion by percutaneous coronary intervention. Patients were
assigned to receive 10 mg/kg G-CSF (56 patients) or placebo (58 patients) for 5 days.
The primary outcome for this analysis was the composite of death, myocardial
infarction or stroke 5 years after randomization.
Results: The endpoint occurred in 7.1% of patients in the G-CSF group versus
15.5% assigned to placebo (relative risk [RR], 0.5; 95% conﬁdence interval [CI],
0.1-1.4; p¼0.17). The combined incidence of death or myocardial infarction
occurred in 5.4% of the patients assigned to G-CSF and 13.8% of the patients
assigned to placebo (RR, 0.4; 95% CI, 0.1-1.4; p¼0.14). The major driver was
mortality which was reduced from 10.3% in the placebo group to 3.6% in the
G-CSF group (p¼0.16).
Conclusions: These long term follow-up data show that G-CSF may reduce
adverse events especially mortality in patients with acute myocardial infarction.
ClinicalTrials.gov Identiﬁer: NCT00126100TCT-822
Effective Antegrade Cardiac Gene Therapy with VEGF-B167 for Pacing-induced
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Background: The selective VEGFR-1 activator VEGF-B has been shown to
be antiapoptotic and cytoprotective in absence of angiogenic side effects. ThusTCT Abstracts/POSTER/Basic Science, Animal Models, and Cell Therapy
